Cancer Home > Ofatumumab Dosage

For people undergoing leukemia treatment with ofatumumab, dosing will largely depend on whether they have used other treatments before or not. The medicine is given as an intravenous (IV) infusion once a week for eight weeks, followed by a dose once a week every four weeks for four doses. You will also receive certain medications before each dose of ofatumumab to help prevent infusion reactions.

An Introduction to Your Dosage of Ofatumumab

There is only one standard dosage of ofatumumab (Arzerra®), regardless of your age or weight. As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.

Ofatumumab Dosing Guidelines

The usual recommended initial dosage of ofatumumab for the treatment of chronic lymphocytic leukemia (CLL) in people who have tried and failed other treatments is 300 mg. After the initial dosage, the amount will be increased to 2000 mg once a week for seven more doses, and then once every four weeks for four doses. Treatment is finished after 12 doses, which normally takes 24 weeks.
For people who have never been on other treatments for CLL, the usual recommended dosage is 300 mg for the initial dosage, followed by 100 mg one week later, and followed by 1000 mg on day 1 of 28-day cycles, for 3 to 12 cycles. For previously untreated people, a regimen of ofatumumab plus chlorambucil is recommended. 
Because of the risk for infusion reactions (serious reactions to the medication that may occur during or shortly after receiving the dose) from the ofatumumab injection, the medication will be given slowly over several hours. The infusion may need to be interrupted if reactions occur.
In addition, your healthcare provider will give you other medicines 30 minutes to 2 hours before each ofatumumab dosage to help prevent infusion reactions. This is known as premedication. Premedication with this particular treatment usually includes the following:
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation




Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.